Biotech drugs contribute heavily to Big Pharma sales
CNN Money had an article back in late May that discusses how the major pharma companies are becoming more like biotechs.
Biotech drugs contribute heavily to Big Pharma sales - May. 29, 2007:
This isn’t too surprising if you consider the fact that biologic drugs have no generic competition. It only makes good business sense to be looking at products have a much longer life-cycle. In 100 years or so, I think it will be difficult to differentiate biotech from pharm in the way we think of them today. I don’t think the small molecule discovery and development will ever go away but I do think you will see budget decisions geared more towards the development of biologicals.
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
June 17th, 2008 at 7:25 pm
The market for biopharmaceuticals is between 70 and 80 million dollars, Only about 20 percent of the 200 or so biotech companies are profitable. The growth annually for biotechs is between 10 and 20 percent.
Yet they are very expensive. Some are 100,000 or more annually, which pays for only a few months of life extension, in large part.